Not much of a poster here in recent years, but have been in DXB since 2016.
The inconclusive result in DKD the Phase 2 trial in 2020 was a disappointment (more a frustration since it might well have been the result of DMX-200 providing unexpected residual benefit post dosing). Dimerix took this in its stride - DKD on the backburner and full steam ahead with FSGS.
Now we are at another inflection point: if the current trial results are positive and the FDA approves Phase 3, we could see a step change in Dimerix - not only running the FSGS trial, but also having the resources to revisit DKD and maybe even start pre-clinical work on DMX-700. DKD itself is a huge potential market.
- Forums
- ASX - By Stock
- DXB
- Dimerix (ASX: DXB) Discussion Thread
Dimerix (ASX: DXB) Discussion Thread, page-516
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.5¢ |
Change
0.030(8.00%) |
Mkt cap ! $225.7M |
Open | High | Low | Value | Volume |
37.0¢ | 40.5¢ | 37.0¢ | $637.2K | 1.624M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 16500 | 40.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 169113 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 16500 | 0.400 |
2 | 12594 | 0.395 |
4 | 90128 | 0.390 |
2 | 100000 | 0.385 |
4 | 268000 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 169113 | 4 |
0.410 | 100000 | 1 |
0.415 | 100000 | 1 |
0.420 | 100000 | 2 |
0.425 | 50507 | 3 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online